NCT00680680View on ClinicalTrials.gov

Treatment of Refractory Urinary Retention Secondary to Benign Prostatic Hyperplasia (BPH) With Dual Five Alpha Reductase Inhibition Combined With an Alpha Blocker

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions

Urinary RetentionBenign Prostatic Hyperplasia

Interventions

DRUG

Dutasteride

Patients will continue on their alpha blocker in addition to Dutasteride 0.5mg daily for a maximum of 3 months

All Listed Sponsors

lead

Franklin D. Gaylis, MD Inc.

OTHER

NCT00680680 - Treatment of Refractory Urinary Retention Secondary to Benign Prostatic Hyperplasia (BPH) With Dual Five Alpha Reductase Inhibition Combined With an Alpha Blocker | Biotech Hunter | Biotech Hunter